In what can be called a major relief for scientists working on cancer research a new study has reassured the potential of a protein that can be targetted to stop tumour growth. Scientists from the University of East Anglia in Britain have found that researchers should not give up on the beta3-integrin protein which has been a major target in cancer drug design for the last two decades. 'These findings have re-established the expression of beta3-integrin as a valid clinical target when treating cancer. Efforts must now be re-focused to either develop new drugs to target beta3-integrin or figure out
